Home › Blog › Weight Loss › NHS vs Private Weight Loss Treatment

NHS vs Private Weight Loss Treatment UK 2026: Eligibility, Waiting Times, Costs and How to Choose

Both routes prescribe the same licensed medicines. What differs is who qualifies, how long you wait, how long treatment is funded for, and what support comes with it. This guide sets out both pathways honestly — including where the NHS route is clearly the better option — so you can work out which one actually applies to you.

NHS vs Private at a Glance

What the NHS Actually Funds

Three separate things get conflated constantly, and separating them explains almost every point of confusion patients arrive with.

• The MHRA licence says who a medicine may legally be prescribed to.
• The NICE recommendation says who the NHS should fund it for.
• Local commissioning and rollout determine who can actually get it, where you live, right now.

A medicine can be licensed for you, recommended by NICE for people like you, and still unavailable to you this year. That is not an error in the system — it is how a phased rollout works when demand vastly exceeds capacity.

Who Qualifies on the NHS

NHS criteria are tighter than the licence in three ways: a higher BMI threshold, a requirement for multiple weight-related conditions, and a phased order of priority that determines when your cohort is reached.

The licensed private criteria, by contrast, are:

Qualifying conditions include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia including raised cholesterol, obstructive sleep apnoea and cardiovascular disease.

For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, a lower BMI threshold is commonly applied — usually reduced by around 2.5 kg/m² — because cardiometabolic risk occurs at lower BMI in these populations. NICE applies this adjustment in its NHS criteria.

Our full Mounjaro eligibility guide and NHS criteria explainer cover both sets of rules in detail.

How the GP Route Works in 2026

The April 2026 change matters, because it moved Mounjaro prescribing into general practice rather than leaving it exclusively with specialist services. Three practical consequences follow.

Participation is voluntary

It is an optional QOF indicator with ring-fenced funding attached. Some practices have taken it up; others have not, usually for capacity reasons. Two people with identical clinical profiles in neighbouring postcodes can therefore have very different access.

Patients are identified from records, not from requests

NHS England has asked patients not to contact their GP to request these medicines. Eligible patients are identified from practice records and contacted directly. Ringing the surgery does not move you up the list, and it adds to the workload that slows the rollout down.

The cohorts widen in stages

The earliest cohorts are those with the highest BMI and the greatest number of weight-related conditions. If you are not contacted, it generally means your cohort has not been reached yet — not that you have been assessed and refused.

Waiting Times

There is no single national figure, and any site quoting one is guessing. Waits for specialist weight management services run from weeks to well over a year depending on area. Where the GP route is operating, timelines depend on practice participation and where your cohort sits in the sequence.

Three things influence your realistic wait more than anything else: your BMI and number of weight-related conditions, whether your practice has opted in, and which ICB area you live in. None of those is within your control, which is precisely why the wait is so hard to plan around.

The Four UK Nations

NICE appraisals apply to England and, through separate arrangements, generally to Wales and Northern Ireland. Scotland has its own process through the Scottish Medicines Consortium. Local implementation, service availability and waiting times differ across all four nations.

If you are outside England, check your own nation’s current position rather than assuming the arrangements described above apply to you.

What Private Clinician-Led Treatment Involves

Private prescribing follows the terms of the UK licence, then narrows according to each provider’s clinical governance. It is not a way around clinical standards — a legitimate private provider applies the same medicines law, the same product warnings and the same professional accountability as any other UK pharmacy.

What it should look like

• A genuine clinical assessment reviewed by a GMC-, GPhC- or NMC-registered prescriber — not an automated score
• Identity and weight verified, rather than a self-reported figure accepted unchecked
• A clinical review before each repeat supply, not just a payment page
• Dose increases decided individually, not escalated automatically on a calendar
• Someone to contact when side effects appear
• A named superintendent pharmacist, a real UK address and a verifiable GPhC registration

The Real Cost Comparison

On the NHS, you pay the standard prescription charge where it applies, and nothing if you are exempt. Privately, you pay in full. That much is obvious. What is less obvious is how to compare private providers against each other, because the advertised price is almost never what you end up paying.

Slinic 2026 Prices

Fixed for 2026. Each pen provides four weekly doses. Prices rise with dose strength because the medicine does — there is no separate charge for the clinical service.

Delivery £4.99 per order. Included in every price: clinical assessment, prescriber review, monthly clinical reviews, needles and swabs, and pharmacist access during treatment. All prices are subject to clinical approval before dispatch — completing an assessment does not guarantee treatment will be approved.

Which Route Is Right for You?

This is a page on a private pharmacy’s website, so take the following in that spirit — but it is what I would tell someone in the consultation room.

The NHS route is the better option if

• You have a high BMI with multiple weight-related conditions — you are likely in an early cohort
• Your practice has opted into the QOF indicator and has contacted you
• You can access a specialist weight management service without a prohibitive wait
• You would benefit from the dietetic and psychological input those services often include
• Cost is the deciding constraint — starting privately and stopping when you cannot sustain it is worse than waiting

Private treatment makes sense if

• You meet the licensed criteria but fall outside the current NHS cohorts — which is the majority of eligible people right now
• Your local wait is measured in many months and your clinical risk is rising in the meantime
• You have been through an NHS course that has reached its funding cap and want to continue
• You want a specific licensed medicine that is not commissioned locally

Moving Between NHS and Private

People move in both directions, and both are entirely legitimate. Three things to get right.

Tell both sides. Your GP should know what you are taking, whoever prescribed it. This matters most for blood pressure and diabetes medicines, which commonly need reviewing as your weight falls — dizziness on standing a few months in is usually a signal that an antihypertensive dose is now too high, not a side effect to endure.

Bring evidence. A dispensing label, prescription record, provider letter or order history showing your medicine, dose and dates. With that, a prescriber can usually continue you at the same strength rather than restarting you at the bottom of the ladder.

Expect a step back after a gap. Tolerance reduces during a break, so returning straight to a high dose after weeks off produces side effects considerably worse than you remember. That is a safety decision, not bureaucracy. Our guide to restarting after a break covers this in full.

What to Ask Any Private Provider — Including Us

• What is your GPhC registration number? Then look it up on the register yourself rather than trusting the display.
• Who is your superintendent pharmacist? A legitimate pharmacy names them.
• Who reviews my assessment, and what are they registered with?
• Can you decline to prescribe? The right answer is yes.
• Is there a clinical review before each repeat, or just a payment?
• Who decides when my dose increases, and what do they look at?
• Who do I contact when side effects appear, and how quickly do they respond?
• How is cold chain maintained in transit?
• Is this a subscription? Can I cancel? Does the price change after month one?
• What is the plan for stopping? Ask this at the start, not at month fourteen.

Common Misconceptions

Frequently Asked Questions

References

1. NICE TA1026 — Tirzepatide for managing overweight and obesity.
2. NICE TA875 — Semaglutide for managing overweight and obesity.
3. NICE NG246 — Overweight and obesity management.
4. NHS England — Weight management injections: access and commissioning.
5. electronic Medicines Compendium — Mounjaro KwikPen Summary of Product Characteristics.
6. electronic Medicines Compendium — Wegovy FlexTouch Summary of Product Characteristics.
7. NHS — Obesity: overview.
8. General Pharmaceutical Council — register of registered pharmacies and pharmacy professionals.
9. MHRA Yellow Card scheme — reporting suspected side effects.

Guidance and commissioning arrangements change. Where this page and current NHS or NICE guidance differ, the official source takes precedence.

Related Guides & Treatment Pages